SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-015846
Filing Date
2023-03-01
Accepted
2023-03-01 07:26:43
Documents
12
Period of Report
2023-02-28
Items
Item 1.03: Bankruptcy or Receivership
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea174454-8k_clarus.htm   iXBRL 8-K 39702
  Complete submission text file 0001213900-23-015846.txt   211872

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE crxtq-20230228.xsd EX-101.SCH 3260
3 XBRL LABEL FILE crxtq-20230228_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE crxtq-20230228_pre.xml EX-101.PRE 22380
6 EXTRACTED XBRL INSTANCE DOCUMENT ea174454-8k_clarus_htm.xml XML 3416
Mailing Address 355 S. GRAND AVENUE, SUITE 1450 LOS ANGELES CA 90071
Business Address 355 S. GRAND AVENUE, SUITE 1450 LOS ANGELES CA 90071 (847) 562-4300
Clarus Therapeutics Holdings, Inc. (Filer) CIK: 0001817944 (see all company filings)

IRS No.: 851231852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39802 | Film No.: 23689782
SIC: 2836 Biological Products, (No Diagnostic Substances)